|
市場調査レポート
商品コード
1276821
ダーマフィラーの世界市場規模、シェア、業界動向分析レポート:タイプ別、製品別、最終用途別、用途別、地域別展望と予測、2023~2029年Global Dermal Fillers Market Size, Share & Industry Trends Analysis Report By Type, By Product, By End-use (MedSpa, Cosmetic Surgery Clinics and Hospitals), By Application, By Regional Outlook and Forecast, 2023 - 2029 |
||||||
ダーマフィラーの世界市場規模、シェア、業界動向分析レポート:タイプ別、製品別、最終用途別、用途別、地域別展望と予測、2023~2029年 |
出版日: 2023年04月28日
発行: KBV Research
ページ情報: 英文 254 Pages
納期: 即納可能
|
ダーマフィラー市場規模は、2029年には103億米ドルに達し、予測期間中にCAGR8.1%の市場成長率で上昇すると予測されています。
HAとコラーゲンは、生分解性で4~9ヶ月の寿命を持つ一時的なダーマフィラーの2つの例です。不満も有害な影響の可能性も、一時的に発生するものです。
そのため、長持ちするフィラーを次回以降に使用するために、一時的なフィラーは常に最初の治療ラインとして採用されます。永久的なフィラーは、一般的な顔のしわの範囲を超えて、皮膚の深いしわや溝を治療するために主に使用されます。特にHIVのリポディストロフィーでは、顔の若返りのための最良の選択と考えられています。PMMAは一般的に、効果的で長持ちし、安全な効果を得るために採用されています。
COVID-19の影響分析
医療用化粧品業界は、COVID-19によるロックダウンにより、輸出入の制限、フライトのキャンセル、生産量の減少、供給ラインの混乱など、サプライチェーンの遅れを経験しました。さらに、ヒアルロン酸やボツリヌス毒素を含む非外科的処置は、総使用量が減少しました。このように、パンデミック時の製品需要の落ち込みは、市場の拡大にさらに影響を及ぼしました。ダーマフィラー市場は、COVID-19のパンデミックの影響を受けています。しかし、COVID-19の症例が減少した後に規制が緩和されたことにより、ダーマフィラー市場は、パンデミック時の損失からの回復を助けることになるでしょう。
市場成長要因
男性におけるフィラー注入の人気上昇
この市場の最も広範な動向の1つは、実質的にすべての人口集団が、低侵襲または非侵襲の施術を望む傾向や素質を示していることです。特に、見た目の美しさを追求する男性にとって、このことは重要です。例えば、重力や加齢が顔の見た目に悪影響を及ぼすことを発見した男性の数は増えています。その結果、男性は、顔の初期の重力による老化を回復させることに成功したため、顔のフィラー施術を選択します。また、回復のためのダウンタイムが必要ないという特別な利点もあります。
より低侵襲な方法の増加
低侵襲手術では、見るためのスコープと専用の器具を使った手術が行われます。しわや小じわなど顔の異常に集中的にアプローチしながら、ボリュームや形、好ましくない脂肪を減らすことができます。低侵襲技術は、重大な副作用のリスクがほとんどなく、切開がほとんど必要なく、回復が早いため、人気が高まっています。しわの減少、肌の引き締め、顔の輪郭の形成、若返りのためのエネルギーベースの低侵襲処置に対する需要は非常に大きいです。これらの要因によって、市場の拡大が促進されると予想されます。
市場抑制要因
ダーマフィラーに関連する高コスト
幅広い美容用途があるにもかかわらず、予測期間中、市場の成長は抑制されると予測されます。市場拡大の鈍化を妨げる主な障壁の1つは、これらの製品に付随する高い価格タグです。ダーマフィラーの価格は、施術の種類、施術者の経験や資格、手術や治療を完了するのに必要な時間や労力など、さまざまな変数によって変化する可能性があります。したがって、ダーマフィラーに関連する高額な費用は、市場の成長を妨げると予想されます。
製品の展望
ダーマフィラー市場は、製品別に、ヒアルロン酸、ヒドロキシルアパタイトカルシウム、ポリ乳酸(PLLA)、ポリメチルメタクリレートマイクロスフィア、その他に分類されます。2022年のダーマフィラー市場では、水酸アパタイトカルシウムセグメントが大きな収益シェアを獲得しました。この成長は、その安全性特性に起因しています。主要企業がこの市場で新商品を発売したことも、このセグメントの拡大に寄与しています。時間の経過とともにコラーゲンを刺激する水酸化アパタイトカルシウム(CaHA)は、注射可能なダーマフィラーの有効成分です。涙袋の周辺を治療することなく、軟部組織のたるみを引き上げ、下眼瞼のたるみを軽減し、涙袋を減少させることができます。
タイプ別展望
ダーマフィラー市場は、タイプ別に生分解性と非生分解性に分類されます。生分解性セグメントは、2022年にダーマフィラー市場で最大の収益シェアを示しました。これは、このセグメントには非生分解性のカテゴリーよりも多くの製品オプションが存在し、生分解性製品はより多様な美容用途を持つためです。また、このセグメントの拡大は、製品の安全性が高く、規制当局の承認がしっかりしていることも後押ししていると予想されます。
用途の展望
ダーマフィラー市場は、用途別に、しわの修正、顔の輪郭形成、傷跡治療、唇の強化、その他に分類されます。2022年のダーマフィラー市場では、リップエンハンスメント部門が突出した収益シェアを獲得しました。これは、唇の施術量が多いことに起因しています。このカテゴリーは、低侵襲処置の出現によって煽られた唇の美容的強化の需要の増加によって牽引されると予測されています。リップフィラーは、唇のボリュームをアップさせることができる美容治療です。
最終用途の展望
ダーマフィラー市場は、エンドユーザーに基づき、メッドスパ、美容外科クリニック、病院に分けられます。病院セグメントは、2022年のダーマフィラー市場において有望な成長率を記録しました。これは、病院で実施される顔面注射などの美容施術が広く普及していることに起因しています。また、ハイテク機器、スタッフ、その他の施設の存在は、様々な種類のフィラー手術に病院を信頼する患者の間で人気を高め、その結果、このセグメントの成長機会をさらに提供しています。
地域別展望
地域別に見ると、ダーマフィラー市場は北米、欧州、アジア太平洋、LAMEAで分析されています。北米地域は、2022年のダーマフィラー市場において最も高い収益シェアを獲得しました。これは、この地域のエイジレスビューティーの発展傾向、男性からの人気の高まり、非外科的な美容処置への欲求の高まりに起因します。北米では、人々は自分の外見や美の基準をとても気にします。このため、顔の特徴を改善し、老化症状を軽減するためのダーマフィラーに対する需要が大きくなっています。
List of Figures
The Global Dermal Fillers Market size is expected to reach $10.3 billion by 2029, rising at a market growth of 8.1% CAGR during the forecast period.
The purpose of dermal fillers is to impart volume and fullness to the skin through injection. A mineral-like substance found in bones called calcium hydroxylapatite, polyalkylimide, hyaluronic acid, polylactic acid, and polymethyl-methacrylate microspheres is among the ingredients utilized in dermal fillers (PMMA).
In addition, the deep dermis, depth of implantation (superficial midterms and upper and subcutaneous levels), the longevity of correction (temporary and permanent), allergenicity, the agent's composition (allografts, semi/fully synthetic, xenografts, or autologous), and stimulatory behavior (physiologic processes of endogenous tissue proliferation) versus replacement fillers are some of the criteria that can be used to classify dermal fillers (space-replacing effect).
HA and collagen are two examples of temporary dermal fillers that are biodegradable and have a lifespan of between four and nine months. Both dissatisfaction and the possibility of detrimental effects are temporary occurrences.
Therefore, in order to save long-lasting fillers for subsequent patient visits, temporary fillers are always employed as the initial line of treatment. Permanent fillers are mostly utilized to treat deep skin wrinkles and furrows that go beyond the scope of typical face creases. They are considered a top choice for face rejuvenation, particularly in HIV lipodystrophy. PMMA is generally employed for effects that are effective, long-lasting, and safe.
COVID-19 Impact Analysis
The medical cosmetics industry experienced supply chain delays due to the COVID-19-imposed lockdowns, which included restrictions on import and export, flight cancellations, decreased production, and disrupted supply lines. Moreover, nonsurgical procedures involving hyaluronic acid and botulinum toxin saw a decline in total usage. Thus, the drop in product demand during the pandemic further impacted the market expansion. The market for dermal fillers has been affected by the COVID-19 pandemic. However, the market for dermal fillers will be driven by the relaxation of regulatory regulations after the decreasing cases of COVID-19, thereby aiding the market to recover after the losses during the pandemic.
Market Growth Factors
The rising popularity of injectable fillers among men
One of the most pervasive trends in the market is that practically all demographic groups have demonstrated a desire or predisposition for these minimally invasive or non-invasive procedures. For the male demographic, who are increasingly using these operations to improve their appearance, this is especially important. For instance, a growing number of men are discovering that gravity and aging can have a detrimental effect on the way their facial features look. As a result, males choose facial filler procedures due to their success in reversing the early gravitational aging of the face. Also, it offers the extra benefit of requiring no downtime for recuperation.
Increasing use of less invasive methods
A scope for seeing and surgical instruments with specialized equipment are used in minimally invasive surgery. It reduces volume, shape, and undesirable fat while concentrating on the abnormalities of the face, such as wrinkles and fine lines. Minimally invasive techniques are becoming more popular because they have almost no risk of significant adverse outcomes and need few or no cuts with quick recovery. There is a huge demand for energy-based, minimally invasive procedures for wrinkle reduction, skin tightening, face contouring, and rejuvenation. These mentioned factors are expected to propel the market's expansion.
Market Restraining Factors
The high cost associated with dermal fillers
The growth of the market is anticipated to be constrained throughout the forecast period, despite the wide range of aesthetic applications. One of the main barriers hindering the slowdown in the expansion of the market is the high price tag attached to these products. Dermal filler prices can vary depending on a variety of variables, including the type of procedure performed, the experience and credentials of the practitioner, and the amount of time and effort necessary to complete the surgery or treatment. Thus, the high cost associated with dermal fillers is expected to hinder the market's growth.
Product Outlook
Based on product, the dermal fillers market is segmented into hyaluronic acid, calcium hydroxylapatite, polylactic acid (PLLA), polymethyl-methacrylate microspheres and others. The calcium hydroxylapatite segment acquired a significant revenue share in the dermal fillers market in 2022. The growth is attributed to its safety characteristics. Key players' launches of new goods in this market also contribute to the segment's expansion. Calcium hydroxylapatite (CaHA), which stimulates collagen over time, is an active constituent in the injectable dermal filler. Without treating the area around the tear trough, one can lift sagging soft tissues, lessen lower eyelid lag, and decrease the tear trough.
Type Outlook
On the basis of type, the dermal fillers market is divided into biodegradable and non-biodegradable. The biodegradable segment witnessed the largest revenue share in the dermal fillers market in 2022. This is due to the presence of more product options in this segment than in the non-biodegradable category and because biodegradable products have more varied aesthetic uses. The segment's expansion is also anticipated to be aided by the goods' higher level of safety and solid regulatory approval.
Application Outlook
By application, the dermal fillers market is classified into wrinkle correction, facial contouring, scar treatment, lip enhancement and others. The lip enhancement segment garnered a prominent revenue share in the dermal fillers market in 2022. This is due to the strong volume of lip procedures. The category is anticipated to be driven by the increased demand for cosmetic enhancements of the lips, fueled by the advent of minimally invasive procedures. Lip fillers are a cosmetic treatment that can enhance the volume of lips.
End-Use Outlook
Based on the end-use, the dermal fillers market is bifurcated into MedSpa, cosmetic surgery clinics and hospitals. The hospital segment recorded a promising growth rate in the dermal fillers market in 2022. This is owing to the widespread use of aesthetic procedures like face injectables carried out in hospitals. In addition, the presence of high-tech equipment, staff and other facilities increased their popularity among patients who trust hospitals for various types of filler surgeries, and thus further providing growth opportunities for the segment.
Regional Outlook
Region-wise, the dermal fillers market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region generated the highest revenue share in the dermal fillers market in 2022. This is due to the region's developing trend of ageless beauty, increased popularity among men, and rising desire for non-surgical aesthetic procedures. In North America, people care a lot about their looks and beauty standards. Due to this, there is a significant demand for dermal fillers to improve face characteristics and lessen aging symptoms.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bioplus Co. Ltd, Bioxis pharmaceuticals, Suneva Medical, Inc., Galderma S.A., Allergan PLC (AbbVie, Inc.), Sinclair Pharma Ltd. (Huadong Medicine Co., Ltd.), Revance Therapeutics, Inc., Medytox Inc., Merz Pharma GmbH & Co. KGaA and Prollenium Medical Technologies Inc.
Strategies Deployed in Dermal Fillers Market
Mar-2023: Galderma revealed FACE by Galderma, an aesthetic visualization tool that enables aesthetic professionals and patients to visualize injectable treatment results. The FACE by Galderma would enable aesthetic professionals to identify and tailor an individualized treatment plan to meet the needs and aesthetic goals of each patient.
Oct-2022: Prollenium Medical Technologies took over SoftFil, the cosmetic aesthetic leader. This acquisition results in creating synergies between the two brands and further expands and strengthens its presence in international markets.
Sep-2022: Revance Therapeutics received US FDA clearance for its DAXXIFY (DaxibotulinumtoxinA-lanm). The approved product provides temporary improvement of moderate to severe frown lines in adults. 2020-Jan: Revance entered into an agreement with Teoxane SA, a Swiss developer of aesthetic medicine. The agreement includes Revance acting as an exclusive distributor for Teoxane's dermal filler products.
Feb-2022: Merz Aesthetics released Radiesse® (+) Lidocaine injectable implant for soft tissue augmentation, enhancing mild to severe jawline contour loss in adults over 21. The launch is aimed at meeting the demand of patients seeking a more defined and contoured jawline.
Jan-2022: Galderma completed the acquisition of ALASTIN Skincare®, Inc, which provides a collection of cutting-edge products for optimal procedure results and daily skincare regimens. The acquisition would enhance the dermatology platform of Galderma with a comprehensive collection of scientifically proven products for daily skincare regimens and post-operative care and reinforce the company's commitment to being aesthetic professionals' partner of choice.
Sep-2021: Galderma joined hands with Sofregen Medical, Inc., a medical device company that uses silk protein for tissue building and regeneration. This collaboration would enhance Galderma's capability to build on decades of biostimulation and hyaluronic acid (HA) filler innovation.
Jun-2021: Medytox received approval from the Taiwan Food and Drug Administration for marketing its botulinum toxin Meditoxin in Taiwan. The Approval would allow the company to expand its business in Southeast Asian countries.
Feb-2021: Sinclair Pharma unveiled Lanluma V, for the face and hands and Lanluma X for the rest of the body. The new products are designed to stimulate collagenases to improve the skin's inner structure and shape, reshape and enhance the fullness of different areas of the body, and reduce cellulite.
Oct-2020: Allergan took over Luminera's dermal filler business. The addition of Luminera's entire dermal portfolio and R&D pipeline improves the acquiring company's dermal filler offerings. Further, Luminera's assets perfectly complement Allergan's JUVEDERM® filler franchise.
Sep-2020: Suneva Medical, Inc. entered into a partnership with Neauvia North America, a subsidiary of Neauvia, a global aesthetics brand. Through this partnership, the company would provide Neauvia North America's Plasma IQ throughout North America. Plasma IQ complements Suneva Medical's portfolio of facial regenerative aesthetics products that would enable the company to offer proven and validated solutions for aesthetic providers and their patients.
Jun-2020: Galderma launched Restylane Kysse, a newly approved lip filler. The Restylane Kysse is a hyaluronic acid (HA) filler that is proven to last for up to 1 year. The product is approved for lip augmentation and the correction of wrinkles around the upper lips.
Jan-2020: Revance entered into an agreement with Teoxane SA, a Swiss developer of aesthetic medicine. The agreement includes Revance acting as an exclusive distributor for Teoxane's dermal filler products.
Sep-2019: Merz expanded its geographical footprint by opening a manufacturing site in Dessau. The new production plant would cater to the evolving demand for its Belotero dermal fillers. Moreover, the location of the new facility to secure the international supply of its medical aesthetics products.
Apr-2019: Merz revealed Belotero Revive, a dermal filler product that contains a combination of hyaluronic acid (HA) and glycerol. The Belotero® Revive is designed to enhance hydration, elasticity, and firmness of the skin and to address the appearance of fine lines.
Market Segments covered in the Report:
By Type
By Product
By End-use
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research